Year: 2018
Type: article
Abstract: The human microbiome is comprised of the bacteria, archaea, viruses, fungi, and other microeukaryotes that live on and within the human host. Alterations in the microbiome are associated with adverse transplant outcomes including the expected infectious complications following allogeneic hematopoietic cell transplantation (allo-HCT) in addition to diseases that are not classically microbe associated. For example, recent data suggest an association between certain microbial community structures and mortality, disease relapse, risk of infection, and graft-versus-host disease (GVHD) [1-3].
Authors: Tessa M. Andermann, Jonathan U. Peled, Christine Ho, Pavan Reddy, Marcie Riches, Rainer Storb, Takanori Teshima, Marcel R.M. van den Brink, Amin Alousi, Sophia Balderman, Patrizia Chiusolo, William B. Clark, Ernst Holler, Alan Howard, Leslie S. Kean, Andrew Y. Koh, Philip L. McCarthy, John M. McCarty, Mohamad Mohty, Ryotaro Nakamura, Katy Rezvani, Brahm H. Segal, Bronwen E. Shaw, Elizabeth J. Shpall, Anthony D. Sung, Daniela Weber, Jennifer Whangbo, John R. Wingard, William A. Wood, Miguel-Angel Perales, Robert R. Jenq, Ami S. Bhatt
Institutions: Stanford Medicine, Stanford University, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Roswell Park Comprehensive Cancer Center, University of Michigan, U-M Rogel Cancer Center, University of North Carolina at Chapel Hill, University of Washington, Fred Hutch Cancer Center, Hokkaido University, The University of Texas MD Anderson Cancer Center, Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic, Virginia Commonwealth University, Virginia Commonwealth University Medical Center, University Hospital Regensburg, Seattle Children's Research Institute, The University of Texas Southwestern Medical Center, VCU Massey Comprehensive Cancer Center, Inserm, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Antoine, Centre de Recherche Saint-Antoine, City Of Hope National Medical Center, City of Hope, University at Buffalo, State University of New York, Medical College of Wisconsin, Duke University, Duke Cancer Institute, Boston Children's Hospital, Dana-Farber Cancer Institute, University of Florida, UF Health Cancer Center, UNC Lineberger Comprehensive Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
Funders: Damon Runyon Cancer Research Foundation, Cancer Prevention and Research Institute of Texas, Regeneron Pharmaceuticals, Jazz Pharmaceuticals, Seres Therapeutics, National Institutes of Health, National Heart, Lung, and Blood Institute, National Cancer Institute, National Center for Advancing Translational Sciences
Awards: G1174881085, G139612635, G1476509662, G1516365345, G1830565468, G1895915179, G2246262118, G2432067426, G285637304, G3119363975, G3713028341, Recruitment of Rising Stars, G4102770861, G4280750938, G4326974628, G4726943279, G6636113147, G777363952, Core Clinical Consortium for Blood and Marrow Transplant Clinical Trials Network, G8848102011, G9000003249, G9000005647, G9000031867, G9000057254, G9000058485, G9000062281, G9000087764, G9000337469, Cancer Center Support Grant, BMT Core- University of Michigan Core Clinical Consortium for the BMT Clinical Trials Network (BMT CTN), A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research, Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc., Cancer Center Support Grant (CCSG)
OpenAlex ID: W2789019684